ALK

(redirected from ALKS)
Also found in: Acronyms.

ALK

Abbreviation for:
activin-like kinase
anaplastic lymphoma kinase, see there

Genetics
A gene on 2p23 that encodes an orphan receptor with tyrosine kinase activity belonging to the insulin receptor superfamily, which plays an important role in brain development.

Molecular pathology
ALK is amplified, mutated and rearranged in various cancers, including anaplastic large cell lymphomas, neuroblastoma and non-small cell lung cancer. The most common genetic alterations seen in ALK malfunction are chromosomal rearrangements resulting in multiple fusion genes, including ALK/EML4, ALK/RANBP2 and ALK/ATIC (all on chromosome 2); ALK/TFG (on chromosome 3); ALK/NPM1 and ALK/SQSTM1 (both on chromosome 5); ALK/KIF5B (on chromosome 10); ALK/CLTC (on chromosome 17); ALK/TPM4 (on chromosome 19); and ALK/MSN (on X chromosome).
References in periodicals archive ?
The company added that ALKS 5461 is a proprietary, investigational, once-daily oral medicine that acts as an opioid system modulator and represents a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
Subsequently, a drug-drug interaction study was performed to identify the ALKS 33 and buprenorphine ratio that would provide complete blockade.
The multicenter, randomized, double-blind, placebo- and active-controlled study was designed to compare the mean change from baseline in body weight in 106 healthy volunteers following three weeks of once-daily, oral administration of ALKS 3831, compared to olanzapine alone or placebo.
In an initial clinical trial, ALKS 33 at 10-mg and 20-mg oral doses completely blocked the effects of serial pulses of remifentanil in opioid-experienced volunteers.
A second phase 2b study of ALKS 37 for the treatment of opioid-induced constipation is concluding, and no additional clinical studies for ALKS 37 are planned.
Biogen will reimburse Alkermes for 50% of the 2017 ALKS 8700 development costs, with Alkermes receiving an upfront payment of USD 28m representing Biogen's share of development expenses already incurred in 2017.
ALKS 3831 is an investigational, novel, oral atypical antipsychotic drug candidate composed of samidorphan, a novel, new molecular entity co-formulated with the antipsychotic agent, olanzapine, in a single bilayer tablet.
We are delighted to present these results to experts in the mental health community at the NCDEU meeting showing that ALKS 5461 offers potential as a novel treatment for patients with MDD who have inadequate response to antidepressant therapy.
This phase 1, randomised, double-blind, placebo-controlled, single-ascending-dose, multi-cohort, four-week study will evaluate the safety, tolerability and pharmacokinetics of the company's ALKS 7106 administered orally in approximately 80 healthy, male adults.
DUBLIN -- Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.
M2 EQUITYBITES-July 31, 2014-Alkermes begins FORWARD-5 pivotal programme of ALKS 5461 for major depressive disorder
M2 PHARMA-July 31, 2014-Alkermes begins FORWARD-5 pivotal programme of ALKS 5461 for major depressive disorder